Connor, Clark & Lunn Investment Management (CC&L)
PVLA

Connor, Clark & Lunn Investment Management (CC&L)’s Palvella Therapeutics PVLA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-878
Closed -$68.5K – 1541
2023
Q1 		$68.5K Sell
878
-535
-38% -$62K ﹤0.01% 1181
2022
Q4 		$118K Sell
1,413
-258
-15% -$20.7K ﹤0.01% 1098
2022
Q3 		$154K Buy
1,671
+565
+51% +$72.8K ﹤0.01% 1015
2022
Q2 		$165K Sell
1,106
-775
-41% -$141K ﹤0.01% 954
2022
Q1 		$456K Sell
1,881
-1,365
-42% -$359K ﹤0.01% 797
2021
Q4 		$982K Buy
3,246
+142
+5% +$45.5K ﹤0.01% 681
2021
Q3 		$1.28M Buy
+3,104
New +$1.08M 0.01% 599

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s PVLA Position: Q2 2023 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Palvella Therapeutics (PVLA) in Q2 2023, closing a stake of 878 shares — an estimated $68.5K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in PVLA in Q3 2021 and held it in 7 quarters. The position peaked at $1.28M in Q3 2021. 49 funds tracked by Wall St. Rank hold PVLA as of Q2 2023.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Palvella Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 878 Palvella Therapeutics shares in Q2 2023, an estimated $68.5K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Palvella Therapeutics in Q3 2021 and held it in 7 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Palvella Therapeutics position peaked at $1.28M in Q3 2021.
  • 49 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2023.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2023, filed 10 Aug 2023.